Business
Glaukos Announces Commercial Availability of Epioxa™, a Transformative Innovation in Interventional Keratoconus Care
ALISO VIEJO, Calif., March 19, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ ("Epioxa"), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated. E
About this update from Glaukos Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/83b7c8a834700018eb112c63c49f6030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2Qh0vv_SfWOxo7BynpxaiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OQ--/https://media.zenfs.com/en/business-wire.com/83b7c8a834700018eb112c63c49f6030","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9bJMqSLKBAzZkD5zy_qqiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg-/https://media.zenfs.com/en/business-wire.com/83b7c8a834700018eb112c63c49f6030","width":1200,"height":224}},"lazy":false},{"type":"text","content":"Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus, a Sight-Threatening Rare Disease","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"ALISO VIEJO, Calif., March 19, 2026--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ ("Epioxa"), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated. Epioxa is now commercially available for ordering directly from Glaukos or through its specialty pharmaceutical distribution network.","length":659,"tagName":"p"},{"type":"text","content":""We are delighted to announce that Epioxa is now commercially available, ushering in a new standard-of-care for patients suffering from keratoconus with the first FDA-approved topical drug therapy that does not require removal of the corneal epithelium," said Thomas Burns, Glaukos chairman and chief executive officer. "Epioxa is designed to improve patient comfort and minimize recovery time, representing a game-changing new interventional keratoconus treatment for patients. Our teams have been diligently preparing for this launch and we are excited to bring this innovative therapy to market for patients."","length":632,"tagName":"p"},{"type":"text","content...